European Commission Approves Nivolumab for Head and Neck Squamous Cell Carcinoma Progressing on or After Platinum-Based Therapy

May 2, 2017 – On April 28, the European Commission approved nivolumab as monotherapy for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults with disease progression on or after platinum-based therapy. Nivolumab is the first and only immuno-oncology treatment that has demonstrated significant improvement in overall survival for these patients in a phase III trial setting. The drug was approved for this indication by the U.S. Food and Drug … (leggi tutto)